Gilead Sciences CEO Daniel O’Day told CNBC on Monday that the company is continuing to study new ways to use its coronavirus treatment remdesivir on patients, including potentially outside of the hospital all together.
“We’re not finished with remdesivir,” O’Day said on “Squawk Box,” one day after the biopharmaceutical company announced a $21 billion acquisition of Immunomedics that will enhance Gilead’s availability of cancer treatments.
Gilead in May received emergency approval for remdesivir from the Food and Drug Administration, allowing it to be used on people who were severely ill with Covid-19 in the hospital. The antiviral drug, which is administered through an intravenous infusion has been shown to help shorten the recovery time of some hospitalized patients.
Reuters reported last week that some large hospital systems in the U.S. are limiting their use of remdesivir to severely ill people. In late August, the FDA expanded its emergency authorization to